Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunotech Biopharm Ltd ( (HK:6978) ) has shared an announcement.
Immunotech Biopharm Ltd has scheduled a board meeting for 20 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The move signals the company is preparing its audited financial disclosures for investors and the market, with the established board, led by chairman and executive director Tan Zheng, overseeing the formal approval process.
The upcoming meeting will determine the final set of figures to be released to shareholders and the wider market, a key step for assessing the company’s performance and outlook. With a full complement of executive, non-executive and independent non-executive directors in place, the governance framework is set to support scrutiny of the results and ensure compliance with Hong Kong listing requirements.
The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a biopharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of immunotherapy and related biotech treatments. The company operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard Hong Kong-listed corporate governance structure.
Average Trading Volume: 567,450
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.46B
Learn more about 6978 stock on TipRanks’ Stock Analysis page.